Search Results - "Najjar, Yana"

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations by Butterfield, Lisa H., Najjar, Yana G.

“…The approval of the first immune checkpoint inhibitors provided a paradigm shift for the treatment of malignancies across a broad range of indications. Whereas…”
Get full text

Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations by Augustin, Ryan C, Delgoffe, Greg M, Najjar, Yana G

“…Immunotherapy (IMT) is now a core component of cancer treatment, however, many patients do not respond to these novel therapies. Investigating the resistance…”
Get full text

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients by Davar, Diwakar, Dzutsev, Amiran K, McCulloch, John A, Rodrigues, Richard R, Chauvin, Joe-Marc, Morrison, Robert M, Deblasio, Richelle N, Menna, Carmine, Ding, Quanquan, Pagliano, Ornella, Zidi, Bochra, Zhang, Shuowen, Badger, Jonathan H, Vetizou, Marie, Cole, Alicia M, Fernandes, Miriam R, Prescott, Stephanie, Costa, Raquel G F, Balaji, Ascharya K, Morgun, Andrey, Vujkovic-Cvijin, Ivan, Wang, Hong, Borhani, Amir A, Schwartz, Marc B, Dubner, Howard M, Ernst, Scarlett J, Rose, Amy, Najjar, Yana G, Belkaid, Yasmine, Kirkwood, John M, Trinchieri, Giorgio, Zarour, Hassane M

“…Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut…”
Get full text

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer by Najjar, Yana G, Finke, James H

“…Tumors escape immune recognition by several mechanisms, and induction of myeloid derived suppressor cells (MDSC) is thought to play a major role in tumor…”
Get full text

Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α by Najjar, Yana G, Rayman, Patricia, Jia, Xuefei, Pavicic, Jr, Paul G, Rini, Brian I, Tannenbaum, Charles, Ko, Jennifer, Haywood, Samuel, Cohen, Peter, Hamilton, Thomas, Diaz-Montero, C Marcela, Finke, James

“…Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC)…”
Get full text

Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? by Najjar, Yana G

“…Most patients with advanced melanoma ultimately fail immune checkpoint inhibitor (ICI) therapy because of primary or acquired resistance. There remains a…”
Get full text

Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma by Najjar, Yana G, Menk, Ashley V, Sander, Cindy, Rao, Uma, Karunamurthy, Arivarasan, Bhatia, Roma, Zhai, Shuyan, Kirkwood, John M, Delgoffe, Greg M

“…The tumor microenvironment presents physical, immunologic, and metabolic barriers to durable immunotherapy responses. We have recently described roles for both…”
Get full text

Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? by Puthanmadhom Narayanan, Susrutha, Najjar, Yana G

Get more information

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy by Pickering, Chad, Aiyetan, Paul, Xu, Gege, Mitchell, Alan, Rice, Rachel, Najjar, Yana G, Markowitz, Joseph, Ebert, Lisa M, Brown, Michael P, Tapia-Rico, Gonzalo, Frederick, Dennie, Cong, Xin, Serie, Daniel, Lindpaintner, Klaus, Schwarz, Flavio, Boland, Genevieve M

“…The clinical success of immune-checkpoint inhibitors (ICI) in both resected and metastatic melanoma has confirmed the validity of therapeutic strategies that…”
Get full text

Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy by Fortman, Dylan, Karunamurthy, Arivarasan, Hartman, Douglas, Wang, Hong, Seigh, Lindsey, Abukhiran, Ibrahim, Najjar, Yana G, Pantanowitz, Liron, Zarour, Hassane M, Kirkwood, John M, Davar, Diwakar

“…CD8+ tumor-infiltrating lymphocyte (TIL) predicts response to anti-PD-(L)1 therapy. However, there remains no standardized method to assess CD8+ TIL in…”
Get full text

Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy by Hicks, William H., Gattie, Lauren C., Shami, Mohamad El, Traylor, Jeffrey I., Davar, Diwakar, Najjar, Yana G., Richardson, Timothy E., McBrayer, Samuel K., Abdullah, Kalil G.

“…Despite advances in the treatment paradigm for patients with metastatic melanoma, melanoma brain metastasis (MBM) continues to represent a significant…”
Get full text

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma by Shaikh, Saba S, Yang, Xi, Fortman, Dylan D, Wang, Hong, Davar, Diwakar, Luke, Jason J, Zarour, Hassane, Kirkwood, John M, Najjar, Yana G

Get full text

An updated analysis of 4 randomized ECOG trials of high‐dose interferon in the adjuvant treatment of melanoma by Najjar, Yana G., Puligandla, Maneka, Lee, Sandra J., Kirkwood, John M.

“…Background The pivotal E1684, E1690, E1694, and E2696 trials of adjuvant high‐dose interferon‐α (HDI) enrolled nearly 2000 patients, and established HDI as the…”
Get full text

Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms by Mkrtichyan, Mikayel, Najjar, Yana G., Raulfs, Estella C., Abdalla, Maher Y., Samara, Raed, Rotem‐Yehudar, Rinat, Cook, Larry, Khleif, Samir N.

“…Programmed death‐1 receptor (PD‐1) is expressed on T cells following TCR activation. Binding of this receptor to its cognate ligands, programmed death ligand…”
Get full text

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis by Bastacky, Melissa L, Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P, Brenner, Timothy, Najjar, Yana G, Luke, Jason J, Kirkwood, John M, Zarour, Hassane M, Davar, Diwakar

“…Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of…”
Get full text

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study by Najjar, Yana G, Navrazhina, Kristina, Ding, Fei, Bhatia, Roma, Tsai, Katy, Abbate, Kelly, Durden, Barbara, Eroglu, Zeynep, Bhatia, Shailender, Park, Song, Chowdhary, Akansha, Chandra, Sunandana, Kennedy, Jonathan, Ernstoff, Marc, Vachhani, Pankit, Drabick, Joseph, Singh, Arun, Xu, Tan, Yang, Jessica, Carvajal, Richard, Manson, Daniel, M Kirkwood, John, Cohen, Justine, Sullivan, Ryan, Johnson, Douglas, Funchain, Pauline, Shoushtari, Alexander

“…BackgroundUveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and…”
Get full text

B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets by Mkrtichyan, Mikayel, Najjar, Yana G, Raulfs, Estella C, Liu, Linda, Langerman, Solomon, Guittard, Geoffrey, Ozbun, Laurent, Khleif, Samir N

“…Programmed death receptor 1 (PD-1) is an important signaling molecule often involved in tumor-mediated suppression of activated immune cells. Binding of this…”
Get full text

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study by Augustin, Ryan C, Huang, Ziyu, Ding, Fei, Zhai, Shuyan, McArdle, Jennifer, Santisi, Anthony, Davis, Michael, Sander, Cindy, Davar, Diwakar, Kirkwood, John M, Delgoffe, Greg M, Warner, Allison Betof, Najjar, Yana G

“…Pre-clinical studies have shown that metformin reduces intratumoral hypoxia, improves T-cell function, and increases sensitivity to PD-1 blockade, and…”
Get full text

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma by Shaikh, Saba S, Zang, Yan, Hanmer, Janel, Wang, Hong, Lin, Yan, Davar, Diwakar, Zarour, Hassane M, Kirkwood, John M, Najjar, Yana G

“…Preclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with…”
Get full text

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab by Najjar, Yana G, Ding, Fei, Lin, Yan, VanderWeele, Robert, Butterfield, Lisa H, Tarhini, Ahmad A

“…In a previously reported study, patients with regionally advanced melanoma were treated with neoadjuvant ipilimumab (ipi) (Tarhini in PLoS ONE 9(2): e87705,…”
Get full text